Karnataka Food Safety and Drugs Administration did what is rare in India’s drug regulation — it cancelled 16 pharmaceutical retail and wholesale licences and suspended eight others, including the depot of multinational Pfizer at Nelamangala. The action was not routine inspection; it was fallout of the Bidadi farmhouse bust on August 18.
At that farmhouse, investigators found a full-scale unlicensed repacking unit. Expired drugs, suspected fakes, oncology vials and ICU injections were being relabelled as expensive imported brands, with expiry dates altered and sold at deep discounts. The label value of the consignment was Rs 5 crore. But the real scandal was distribution — the network had supplied to more than 90 hospitals and clinics across the state through a Bengaluru pharmacy nexus.
Cancelling licences sends a signal, but it also raises a harder question: how did a farmhouse become a supplier to 90 hospitals without any red flag in the drug supply chain? Private hospitals buying discounted drugs outside authorised channels hints at complicity, or at least wilful blindness, in procurement for profit.
India wants to be pharmacy of the world, yet its domestic pharmacovigilance is porous. Recent cough syrup deaths linked to contaminated exports and now cancer drugs faked domestically point to same failure — no end-to-end traceability. Karnataka has formed a Special Investigation Team, is probing inter-state links, and chasing one accused abroad. But the antidote is systemic: mandatory QR-coded batch tracking from factory to patient, real-time inventory audits, and criminal liability for hospitals that cannot prove source. Until then, every licence cancellation will be after-the-fact justice for patients who already consumed fake medicine.